Corvus Pharmaceuticals, Inc. (CRVS) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-06-15

Corvus Pharmaceuticals, Inc. (CRVS) has filed 7 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-06-15. 4 Form 8-K material event filings were reported by CRVS in the last 90 days. InsiderAlpha tracks every CRVS SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About Corvus Pharmaceuticals, Inc. (CRVS)

SIC classification	Pharmaceutical Preparations (SIC 2834)
SEC CIK	0001626971

90-Day SEC Filing Activity

Form 4 filings (90d)	7
Form 8-K filings (90d)	4
Latest Form 4 filing	2026-06-15

Recent CRVS Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-06-11	Moore David Scott	Insider	P — Open-market purchase	21.7K	$11.53	$250K	SEC
2026-05-18	MILLER RICHARD A MD	President and CEO	P — Open-market purchase	5.0K	$12.05	$60K	SEC
2026-05-18	MILLER RICHARD A MD	President and CEO	P — Open-market purchase	1.9K	$12.01	$23K	SEC
2026-01-28	Thompson Peter A.	Director	M — Option exercise	15.0K	$3.27	$49K	SEC
2026-01-28	Thompson Peter A.	Director	M — Option exercise	15.0K	$0.99	$15K	SEC
2026-01-28	Thompson Peter A.	Director	M — Option exercise	15.0K	$0.96	$14K	SEC
2026-01-28	Thompson Peter A.	Director	M — Option exercise	15.0K	$2.49	$37K	SEC
2026-01-28	Thompson Peter A.	Director	M — Option exercise	15.0K	$1.64	$25K	SEC
2026-01-28	Thompson Peter A.	Director	M — Option exercise	15.0K	$2.12	$32K	SEC
2026-01-28	Thompson Peter A.	Director	M — Option exercise	30.0K	$15.00	$450K	SEC
2026-01-28	Thompson Peter A.	Director	M — Option exercise	15.0K	$9.70	$146K	SEC
2026-01-28	Thompson Peter A.	Director	M — Option exercise	15.0K	$12.50	$188K	SEC
2026-01-28	Thompson Peter A.	Director	M — Option exercise	15.0K	$3.61	$54K	SEC
2026-01-28	Thompson Peter A.	Director	M — Option exercise	15.0K	$2.00	$30K	SEC
2026-01-28	Thompson Peter A.	Director	M — Option exercise	15.0K	$2.74	$41K	SEC

All transactions sourced from SEC EDGAR Form 4 filings for Corvus Pharmaceuticals, Inc. (CRVS). Updated in real time as new filings are submitted to the SEC.

Most-Active CRVS Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
Moore David Scott	2	$250K
MILLER RICHARD A MD	2	$83K
Thompson Peter A.	1	—
Chan Andrew C.	1	—
Grais Linda	1	—

Recent CRVS Form 8-K Material Events

2026-06-12 — Item 5.07 [SEC]
2026-05-14 — Item 7.01, 8.01, 9.01 [SEC]
2026-05-07 — Item 2.02, 9.01 [SEC]
2026-04-23 — Item 5.02 · Leadership · neutral [SEC]
Corvus Pharmaceuticals appointed Andrew C. Chan, M.D., Ph.D. to its Board of Directors as a Class II director effective April 23, 2026. Dr. Chan was also appointed to the Nominating and Corporate Governance Committee and will receive standard non-employee director compensation in
2026-03-13 — Item 1.01, 9.01 · Financing · neutral [SEC]
Corvus Pharmaceuticals entered into an Amended and Restated Open Market Sale Agreement with Jefferies LLC on March 13, 2026, increasing the maximum aggregate offering price from $100 million to $200 million. The company may sell shares of common stock from time to time through an

Recent Insider Filings

2026-06-15 — Moore David Scott (Insider)
2026-06-15 — CLARK IAN T (Insider)
2026-06-15 — Grais Linda (Insider)
2026-06-15 — Thompson Peter A. (Insider)
2026-06-15 — van den Broek Richard (Insider)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in CRVS insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

CRVS Insider Trading — FAQ

What is the latest insider trade for CRVS?: Corvus Pharmaceuticals, Inc. (CRVS) had 7 insider filings in the last 90 days, with the most recent on 2026-06-15. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying CRVS stock?: 0 insider purchases of CRVS were filed in the last 90 days.
How many insiders are selling CRVS stock?: 0 insider sales of CRVS were filed in the last 90 days.
Where can I see CRVS SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every CRVS SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Related Companies — Recent Insider Activity

Learn More

Open the live CRVS dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.